论文部分内容阅读
目的了解深圳市乙型肝炎病毒(HBV)基因分型情况,探讨HBV基因分型与抗病毒治疗疗效及预后的关系。方法用单克隆抗体ELISA法(mAbsELISA)对143例乙型肝炎病毒感染的患者进行HBV基因分型。结果143例患者中,B型67.8%,C型26.6%。B型多见于无症状乙型肝炎病毒携带者(ASC)(95.4%);C型多见于肝硬化患者(LC)(64.7%)。年龄≤35岁及有乙型肝炎家族史的患者中B型均较C型多见(P<0.05)。拉米夫定治疗的LC中,HBVDNA持续阴性者B型较C型多见(P<0.05)。干扰素治疗的慢性乙型肝炎患者中,完全应答者B型较C型多见(P<0.05)。25例重型乙型肝炎患者中,B型存活(94.1%)较C型存活(57.1%)高(P<0.05)。结论深圳地区HBV基因分型以B型为主,C型次之。B型多见于年轻患者,C型多见于年老患者,且C型肝硬化患者对拉米夫定疗效差。
Objective To understand the genotyping of hepatitis B virus (HBV) in Shenzhen and to explore the relationship between HBV genotyping and the efficacy and prognosis of antiviral therapy. Methods 143 patients with hepatitis B virus infection were genotyped by using monoclonal antibody ELISA (mAbsELISA). Results Among the 143 patients, type B 67.8% and type C 26.6%. Type B more common in asymptomatic hepatitis B virus carriers (ASC) (95.4%); C type more common in patients with cirrhosis (LC) (64.7%). Type B was more common in patients ≤35 years of age and in patients with a family history of hepatitis B than in type C (P <0.05). Among the lamivudine-treated LCs, patients with persistent negative HBVDNA had more type B than type C (P <0.05). Interferon treatment of chronic hepatitis B patients, complete response B type more than C type more common (P <0.05). Among 25 patients with severe hepatitis B, survival of type B (94.1%) was higher than that of type C (57.1%) (P <0.05). Conclusion HBV genotypes in Shenzhen are mainly type B and type C is the second. B-type more common in young patients, C-type more common in elderly patients, and C-type cirrhosis patients lamivudine poor efficacy.